Intas Pharma has entered an exclusivity agreement with IntegriMedical for their needle‑free injector technology to be used in in‑vitro fertilisation and gynaecology. This partnership represents a significant milestone for Intas Pharma, as needle‑free injectors offer an advanced method of drug delivery that improves patient comfort, enhances compliance, and optimises the overall treatment experience, particularly in women’s health and IVF care.
By securing exclusive rights to IntegriMedical’s technology, Intas Pharma aims to strengthen its differentiated offerings for the first time globally in this segment. The needle‑free delivery system allows medications to be administered without traditional needles, reducing discomfort for patients undergoing multiple injections as part of IVF protocols and other gynaecological treatments.
The collaboration underlines Intas Pharma’s commitment to introducing innovative, patient‑centric solutions in reproductive and women’s healthcare.
